Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (251)
  2. Journal Article (99)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (3)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (375)
  2. Department of Medicine (375)
  3. Hematologic Malignancies Research (375)
  4. Hematologic Malignancies, Division of (375)
  5. Myeloma (375)
  6. Survivorship Research (221)

More Groups

People
  1. Hani Hassoun (199)
  2. Heather Landau (184)
  3. Sergio Giralt (182)
  4. David Chung (174)
  5. Neha Korde (170)
  6. Sham Mailankody (167)

More People

Years
  1. 2025 (6)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (40)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (11)

More Publications

Publishers
  1. American Society of Hematology (151)
  2. Elsevier Inc. (78)
  3. American Society of Clinical Oncology (40)
  4. Nature Publishing Group (24)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (375)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MALDI-TOF mass spectrometry in serum for the follow-up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Meeting Abstract

    Eveillard, M.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Smith, E. L.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Korde, N.; Landgren, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft purity with novel induction regimens in multiple myeloma
    Meeting Abstract

    Bal, S.; Landau, H.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Hassoun, H.; Hultcrantz, M.; Korde, N. S.; Lesokhin, A. M.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Depth of response and outcomes by initial therapy prior to autologous hematopoietic stem cell transplantation for multiple myeloma
    Meeting Abstract

    Shah, G.; Chung, D.; Scordo, M.; Seier, K.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lesokhin, A.; Mailankody, S.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Practice patterns with focal progression on daratumumab therapy
    Meeting Abstract

    Bal, S.; Peterson, T.; Landau, H.; Chung, D.; Giralt, S.; Korde, N.; Mailankody, S.; Smith, E.; Shah, U.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft purity with novel induction regimens in multiple myeloma
    Meeting Abstract

    Bal, S.; Landau, H.; Shah, G.; Scordo, M.; Dahi, P.; Lahoud, O.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Meeting Abstract

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Korde, N.; Lendvai, N.; Hassoun, H.; Lesokhin, A. M.; Lahoud, O. B.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma
    Meeting Abstract

    Atkins, M. B.; Kirkwood, J. M.; Wolchok, J. D.; Callahan, M. K.; Kluger, H. M.; Postow, M. A.; Segal, N. H.; Lesokhin, A. M.; Balogh, A.; Re, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Hematologic toxicities of apparent immune-related origins
    Book Section

    Chen, G. L.; Robert, C.; Lesokhin, A. M.
    In Ernstoff, M. S.; Puzanov, I.; Robert, C.; Diab, A.; Hersey, P. (Eds.) SITC's Guide to Managing Immunotherapy Toxicity (2019)

    Fulltext@MSK | Save